Skip to content
Back
  • Home
  • About us
    • Management
    • Board
    • Team
    • Scientific advisory board
    • Partnerships
    • Investors
  • Our science
  • Pipeline
    • Pipeline
    • CP-012
    • CP-101
    • CP-102
    • CP-301
    • CP-107
    • CP-108
  • News
    • Press releases
  • Contact
    • Business Development
    • Social network
    • Career

Current
Pipeline

See our pipeline

* License to formulation technology with BDD Pharma, UK

** Contera Pharma has the first option right to enter exclusive worldwide license

# Small molecule

Recent News

September 17, 2025
Contera Pharma announces positive topline results in Phase 1b trial of CP-012, a novel therapy to treat nocturnal immobility and morning akinesia in Parkinson’s disease
Hørsholm, September 17, 2025 - Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced positive topline…
Read more
August 28, 2025
Contera Pharma announces last patient dosed in Phase 1b trial of CP-012, a novel therapy to treat nocturnal symptoms and morning akinesia in Parkinson’s disease
Hørsholm, August 28th, 2025 – Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, today announced that the…
Read more

View all news

Contact us

Denmark map icon

Contera Pharma

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

Thomas Sager, CEO
info@conterapharma.com

 

Contact us

Contera Pharma

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

 

Thomas Sager, CEO

info@conterapharma.com

 

Connect on Linkedin

Useful links

About us

Our Science

Pipeline

News

Contact

Cookie policy

Privacy policy